Cdc25C is a dual-specificity phosphatase that is involved in induction of mitosis by removal of the inhibitory phosphates from cyclin-dependent kinase 1/cyclin B.
Introduction
Cancer arises due to abnormalities to DNA. The major protective mechanisms against development of cancer are the cell cycle checkpoints (1) . Activation of the cell cycle checkpoints in response to DNA damage results in either preventing the cells from entering the next phase of the cell cycle to allow repair or inducing cell death if the lesion is beyond restoration. The two predominant checkpoints include those in the G 1 and G 2 phases. The former prevents the cells from entering S phase and replicating damaged DNA and the latter inhibits entry into mitosis and propagation of damaged DNA to daughter cells. It has been proposed that the G 1 checkpoint is disabled in the majority of cancers as a prerequisite for tumorigenesis (2, 3) . The G 2 checkpoint, however, appears to remain functional in the majority of cancer cells. Many conventional cancer therapeutic agents exert their effects by causing DNA damage. Thus, retaining a functional G 2 is believed to confer resistance to many such therapeutic agents. To circumvent this, attempts have been made to develop abrogators of this arrest in the G 2 phase (4). Furthermore, the success of such a strategy would provide the fundamental advantage of selectively targeting cancer cells. Thus, cancer cells unable to arrest at the G 2 -M border will die in response to treatment, whereas their normal counterparts will still arrest at the G 1 border.
At the molecular level, the lack of a G 1 arrest in cancer cells is a result of their inability to inhibit cyclin-dependent kinase (Cdk) 2, the kinase that is considered to be important for entry into S phase (1, 5) . This usually arises as a consequence of a dysfunctional p53 and/or Rb pathway (1, 2) . The target for the G 2 checkpoint pathway is Cdk1 (1) . Cdk1, once activated, ushers the cell into mitosis and subsequent cell division (5) . Activity of Cdk1 is regulated at several levels. The final step in activation of Cdk1 is removal of the inhibitory phosphates from Thr 14 and Tyr 15 . In mammalian cells, there are three related dual-specificity phosphatases, Cdc25A, Cdc25B, and Cdc25C, which act to dephosphorylate these residues (6) . To arrest the cells at the G 2 -M border, dephosphorylation of Cdk1 on the two inhibitory residues is prevented by inhibiting the activities of these three phosphatases by various mechanisms (1, 6 -13) . The kinase Chk1 is a major regulator of the G 2 checkpoint, as it is capable of inactivating all three phosphatases via their phosphorylation (1) .
Many of the players in the G 2 checkpoint pathway including Chk1 have been proposed or tested as means to abrogate the G 2 arrest (4). In addition, other approaches have included drugs such as caffeine and UCN-01 (4) . The major problems with these candidates have been their involvements in other cellular processes leading to unwanted toxicities. A recent study described a peptide, CBP501, which prevents phosphorylation of Cdc25C on Ser 216 in response to DNA damage and thus abrogates G 2 arrest (14) . Phosphorylation of this site is required for retaining Cdc25C in the cytoplasm and thereby preventing activation of Cdk1 when DNA is damaged (11, 12) . CBP501 selectively enhanced sensitivity of cancer cells to genotoxic cancer therapy drugs in the absence of side effects (14) . Thus, Cdc25C is suggested to be a useful target when considering strategies for abrogating G 2 arrest. Here, it is proposed that overexpression of Cdc25C may be another means to abrogate the G 2 checkpoint. Overexpression or lack of Cdc25C does not affect progression through the normal cell cycle in different cell lines in short-term or long-term assays. Loss of Cdc25C also does not affect the G 2 arrest response to doxorubicin, a widely used anticancer drug that exerts its effects by inducing damage to genomic DNA by a variety of proposed mechanisms, notably inhibition of topoisomerase II (15) . Nevertheless, excess amount of Cdc25C converts the G 2 arrest induced by doxorubicin to cell death in several tumor cell lines. In contrast, overexpression of Cdc25C does not interfere with arrests in other phases of the cell cycle caused by treatment with either 5-fluorouracil (5-FU) or hydroxyurea.
Materials and Methods
Cell Cultures and DrugTreatments Human U2OS, HCT116-p53 À/À , and H1299 cells were grown as monolayers in DMEM (Life Technologies/ Invitrogen) supplemented with 10% FCS (Life Technologies/Invitrogen) and 100 units/mL penicillin/streptomycin (Life Technologies/Invitrogen) at 5% CO 2 and 37jC. MCF10A cells were grown in DMEM/F12 with 15 mmol/L HEPES, 5% horse serum, 10 Ag/mL insulin, 20 ng/mL human epidermal growth factor, 100 ng/mL cholera toxin, 0.5 Ag/mL hydrocortisone, and 100 units/mL penicillin/ streptomycin. Dose-response curves were done to determine the optimal concentration for each drug and cell line. Exponentially growing cells were treated with various drugs as follows: U2OS, HCT116p53 À/À , and H1299 received 0.2 Ag/mL doxorubicin, 400 Amol/L 5-FU, or 1.5 mmol/L hydroxyurea. MCF10A cells received 0.05 Ag/mL doxorubicin, 300 Amol/L 5-FU, or 1 mmol/L hydroxyurea.
Construction of Recombinant Cdc25C Adenovirus
The recombinant Cdc25C adenovirus was constructed as described (16). Briefly, the FLAG-tagged open reading frame of Cdc25C was subcloned into the pAdTrack-CMV shuttle vector. It was then linearized by digestion with PmeI and was cotransformed together with the adenoviral backbone plasmid, pAdEasy-1, into the homologous recombination-competent Escherichia coli strain BJ5183. The resultant recombinant was linearized with PacI and transfected into the adenovirus packaging cell line, 293T. High titer of recombinant adenovirus was obtained by several rounds of infection.
Flow Cytometric Analysis Cells were fixed in ice-cold 70% ethanol followed by rinsing with PBS. DNA was stained with propidium iodide (20 Ag/mL; Sigma) in the presence of 1 mg/mL RNase A (Sigma). Cell cycle analysis was done on a FACSCalibur and data were analyzed using CellQuest.
Immunoblotting
Cells were lysed in a buffer containing 50 mmol/L HEPES, 150 mmol/L NaCl, 1 mmol/L EDTA, 1% Triton X-100, 0.1 mmol/L Na 3 VO 4 , 10 mmol/L NaF, 80 mmol/L glycerophosphate, 1 mmol/L phenylmethylsulfonyl fluoride, 20 units/mL aprotinin, 5 mg/mL leupeptin, and 5 mg/mL pepstatin. Lysates were clarified by centrifugation (10,000 Â g for 10 min at 4jC) and immunoblotted. The following antibodies were used: anti-FLAG M2 was purchased from Sigma. Anti-Cdc25A (F-6), anti-Cdc25C (H-6), anti-Cdk1 (C-19), and anti-pT 14 /Y 15 Cdk1 were from Santa Cruz Biotechnology. Anti-poly(ADP-ribose) polymerase was from BP Pharmicon. Antibody to h-actin was from Oncogene Research Products. Peroxidase-conjugated goat antibodies against rabbit or mouse IgG (MP Biomedicals) were used as secondary antibodies. The signals were detected using enhanced chemiluminescence reagents (Amersham Biosciences) and autoradiography films (Labscientific).
Immunostaining Cells were grown on coverslips (Fisher Scientific). After fixation in 3% paraformaldehyde, cells were washed in PBS and permeabilized in a solution containing 0.5% Triton X-100, 3 mmol/L MgCl 2 , and 0.2 mmol/L sucrose. After washing in PBS, cells were blocked in 3% bovine serum albumin in PBS for 10 min before incubation with the same buffer but containing a 1:1,000 dilution of mouse anti-FLAG antibody (Upstate, Cell Signaling Solutions) for 1 h. The cells were then washed in PBS and subsequently incubated with 1:2,000 dilution of Alexa Fluor 545 goat anti-mouse IgG (Molecular Probes, Invitrogen Detection Technologies) in 3% bovine serum albumin in PBS for 1 h. DNA was stained with 4 ¶,6-diamidino-2-phenylindole (Sigma) at a concentration of 5 mg/mL PBS. The cells were then washed in PBS. The coverslips were mounted on microscope slides (Fisher Scientific) covered with ImmuMount oil (Thermo Electron). The coverslips were sealed with transparent nail polish. The cells were observed using a fluorescence microscope (Nikon Eclipse E800).
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide and Apoptosis Assays 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were done according to the manufacturer's instructions (Sigma). For detection of apoptotic cells, staining was done with Annexin V-PE and then analyzed by flow cytometry according to the manufacturer's protocol (BD Pharmingen).
Small Interfering RNA Exponentially growing U2OS cells were transfected with SMARTpool reagent containing Cdc25C or Cdc25A small interfering RNA oligonucleotides or control oligonucleotides (Dharmacon, RNA Technologies) using DharmaFECT reagent 1 (Dharmacon) following manufacturer's instruction.
Results

Overexpression of Cdc25C Sensitizes U2OS Tumor Cells to Doxorubicin-Induced Apoptosis
Phosphorylation of Cdc25C by Chk1 and its subsequent cytoplasmic sequestration or its down-regulation by p53
Cdc25C Enhances Chemotherapeutic Response has been shown to contribute to the G 2 -M arrest caused by genotoxic stress (11, 12, 17) . Thus, the ability of overexpression of Cdc25C to overcome this G 2 -M arrest was examined. U2OS cells were infected with either two different amounts of a recombinant adenovirus expressing Cdc25C (Ad-25C) 1 day before treatment with doxorubicin (0.2 Ag/mL) or empty vector with the same multiplicity of infection as the highest level of Ad-25C ( Fig. 1) . At this time point, more than 95% of cells were infected as judged by microscopic evaluation of green fluorescent protein expression (data not shown). Uninfected U2OS cells were included as a control. The cell cycle profiles of these cells were examined 2 days after drug treatment by flow cytometry analysis ( Fig. 1A and B) . Control U2OS cells or those infected with empty adenovirus were able to arrest with a 4N DNA content consistent with a G 2 arrest ( Fig. 1A and B). U2OS cells overexpressing Cdc25C, however, were unable to maintain the G 2 arrest and accumulated with a hypodiploid DNA content ( Fig. 1A and B) . Interestingly, loss of the G 2 arrest was inversely proportional to the amount of the exogenous levels of Cdc25C (Fig. 1C) . Levels of p53 and p21 induction in the presence of high levels of Cdc25C appear decreased (Fig. 1C ), but it is unclear whether this is a direct effect or related to the use of adenoviral infection. Cells infected with these levels of Cdc25C were able to proliferate until confluency in the absence of drug treatment, indicating that these levels of Cdc25C do not disturb their normal proliferation (data not shown). Accumulation of cells with a hypodiploid DNA content is consistent with cell death by apoptosis. This was further confirmed by examining cleavage of poly(ADP-ribose) polymerase, a known target for apoptosis-associated caspase cleavage (Fig. 1C) .
U2OS Tumor Cells That Are Stably Overexpressing Cdc25C Are Sensitized to Doxorubicin-Induced Apoptosis
Out of concern that some of the observed effects may be a consequence of adenoviral infection, stable U2OS cell (Fig. 2) . Consistent with results obtained from cells infected with Ad-25C, Cdc25C-overexpressing clones were unable to maintain an arrest at the G 2 -M phases and this occurred in a manner dependent on the levels of Cdc25C. The results of two representative clones expressing different amount of Cdc25C are shown ( Fig. 2A and B) . Twenty-four hours after drug treatment, only 1% to 2% of the control cells were found with a 2N DNA content representing the G 1 phase. The majority of the cells were found to have a DNA content of 4N ( Fig. 2A) . At the same time point, higher levels of Cdc25C were associated with increases in the number of cells found in the G 1 and S phases and consequently less in the G 2 -M phases ( Fig. 2A) . At later time points, in a manner that correlates with the level of exogenous Cdc25C, cells overexpressing Cdc25C were unable to maintain their G 2 arrest and subsequently died by apoptosis as judged by the increased number of cells with a sub-G 1 DNA content ( Fig. 2A and B) . Excess amount of Cdc25C did not affect other behaviors of these cells that were examined such as proliferation rate or morphology compared with the parental cells even after several passages (data not shown). This suggests that these levels of Cdc25C are tolerated by U2OS cells.
To examine the effects of Cdc25C overexpression on a single-cell basis, immunofluorescence analyses were done using clone 18, which expresses higher levels of Cdc25C (see Fig. 3A ). In exponentially growing cells, exogenous Cdc25C was found to be both cytoplasmic and nuclear (Fig. 2C) . p53 is a substrate for the ATM and ATR kinases that are activated in response to DNA damage, with Ser 15 on p53 as a primary site for modification by these kinases. The intensity and frequency of positivity for p53 that is phosphorylated on Ser 15 is similar between the control and clone 18. In agreement with the flow cytometry analyses, at 4 days after drug treatment, the clone 18 cells that overexpress Cdc25C were found to display morphologic evidence of apoptosis ( Fig. 2C; Supplementary Fig. S1 ). 1 Some of these cells appear to have reduced staining with the anti-FLAG antibody. This is likely due to cells that are in the late stages of apoptosis showing reduced expression of multiple proteins including the FLAG-tagged Cdc25C and Cdk1 (Fig. 3A) as well as p53 itself (Fig. 3B) . Taken together, these results are consistent with abrogation of the G 2 arrest leading to subsequent entry into mitosis with damaged DNA (18, 19) .
U2OS Cells That Overexpress Cdc25C Have Reduced Phosphorylation of Cdk1 on Tyr 15 and Impaired UpRegulation of p21 in Response to Treatment with Doxorubicin Phosphorylation of Cdk1 on Thr 14 and Tyr 15 has been shown to be important for induction of G 2 -M arrest (1). Thus, the status of phosphorylation of these residues was examined in immunoblotting assays. As shown in Fig. 3A , in control cells, phosphorylation of these residues increased 1 day after drug treatment. In Cdc25C-overexpressing cells, the level of Cdc25C appeared to be a determining factor. In clone 4 that expresses lower levels of Cdc25C, an increase in phosphorylation of Cdk1 on these residues was observed at 1 day, suggesting that these levels of Cdc25C do not affect significantly the initial phosphorylation of Cdk1 on these residues. However, in this clone, phosphorylation of these residues was not maintained as long as in control cells (Fig. 3A) . Higher amount of Cdc25C in clone 18, however, showed little phosphorylation of these residues (Fig. 3A) . These results are consistent with the results of flow cytometry analyses at these time points (Fig. 2) .
To further confirm that overexpression of Cdc25C overcomes the G 2 arrest, immunoblotting using antibody against phosphorylated histone H3 on Ser 10 (pSer 10 H3), a marker of mitosis, was done (Fig. 3A) . In control cells, little pSer 10 H3 was detected at any examined time points after drug treatment (Fig. 3A) . In Cdc25C-overexpressing cells, the higher the amount of Cdc25C, the more pSer 10 H3 was detected (Fig. 3A) . Levels of total p53 as well as the amount of p53, which is phosphorylated on Ser 15 , were determined. Overexpression of Cdc25C did not affect the level of p53 induction (Fig. 3B) . Consistent with the immunofluorescence results, the amount of p53 that is phosphorylated on Ser 15 was unchanged (Fig. 3B ). Mdm2 is a target for p53 transcriptional up-regulation. High levels of Cdc25C did not interfere with the amount of Mdm2 that is up-regulated in response to doxorubicin treatment (Fig. 3B) . Intriguingly, however, the increase in levels of another p53 target, the Cdk inhibitor p21, was delayed and impaired in cells with high levels of Cdc25C (Fig. 3B) . As p21 has been characterized as playing a key role in cell cycle arrest checkpoints, the lower levels of p21 in the Cdc25C-expressing cells may contribute to the failure to maintain the G 2 checkpoint. Indeed, p21-null cells are exquisitely sensitive to DNA damage even in the absence of Cdc25C overexpression ( Supplementary Fig. S2 ). The role of Cdc25C overexpression in other cell cycle checkpoints was then examined. To investigate the effect of excess amount of Cdc25C on cell cycle arrest in G 1 -S or S phase of the cell cycle, Cdc25C-overexpressing U2OS clones or control cells were treated with either of two agents that are known to induce arrests at the G 1 -S-phase border (20) . 5-FU and hydroxyurea are inhibitors of Cdc25C Enhances Chemotherapeutic Response pyrimidine synthesis or both purine and pyrimidine synthesis, respectively (20) . Flow cytometry analyses of cell cycle profiles of U2OS cells treated with these drugs at the indicated time points are shown in Fig. 4C and D. Cell cycle profile of the control cells in response to 5-FU was consistent with both G 1 -S and G 2 arrests (Fig. 4C) . In these cells, f50% of cells were found to have a DNA content of 4N by 2 days (Fig. 4C) . Interestingly, consistent with Cdc25C abrogating the G 2 arrest, high levels of Cdc25C caused a reduction in the number of cells with 4N DNA content and a corresponding increase in that of cells with 2N DNA content in a manner that correlated with Cdc25C level of expression (23% in clone 4 and 16% in clone 18; Fig. 4C ). Under these conditions, the cells that escaped the G 2 arrest did not die but become arrested in the G 1 phase. In response to hydroxyurea, the majority of the control cells accumulated with a S-phase DNA content at 2 days following drug treatment (Fig. 4D) . This was more predominant in Cdc25C-overexpressing clones in a manner dependent on the levels of exogenous Cdc25C (Fig. 4D) . These results show that excess amounts of Cdc25C only override the G 2 arrest caused by doxorubicin and 5-FU and have no effect on the G 1 -S arrest caused by treatment with 5-FU and hydroxyurea. Further, there is no evidence of apoptosis in the Cdc25C-expressing cells in response to either of these agents.
Sensitization of Tumor Cells to Doxorubicin-Induced Apoptosis by Overexpression of Cdc25C Is Not p53 Dependent U2OS cells are osteosarcoma cells that express wild-type p53. To determine the role of p53 status in the ability of overexpression of Cdc25C to overcome the G 2 arrest, two cell lines, H1299 (lung carcinoma) and HCT116-p53 À/À (colon carcinoma), which lack p53 expression, were tested. Both cell lines were treated with similar protocols. Infection of these cells with Ad-25C did not influence cell cycle profiles of these cells as observed by flow cytometry analyses (Fig. 4A and B) . The expression from Ad-25C was confirmed by microscopic analyses of expression of green fluorescent protein (data not shown). Infection with Ad-25C, however, abolished the G 2 arrest in both cell lines (Fig. 4A and B) . As observed in U2OS cells, elevated levels of Cdc25C did not affect the G 1 -S-phase arrest caused by 5-FU or hydroxyurea (Fig. 4A and B) . Thus, excess amounts of Cdc25C are capable of abolishing G 2 arrest in cell lines from different origins and regardless of p53 status.
Nontransformed MCF10A Cells Are Not Sensitized to Doxorubicin-Induced Apoptosis by Overexpression of Cdc25C MCF10A cells are a nontransformed breast epithelial line. These cells were infected with Ad-25C to investigate the effect of overexpression of Cdc25C on cells that were not of tumorigenic origin. Ad-25C infection did not affect the normal cell cycle profile of these cells (Fig. 5A) . This same amount of Ad-25C, however, was capable of overcoming the accumulation of cells with a 4N DNA content caused by treatment with doxorubicin showing an increase in cells in the G 1 phase and a corresponding decrease in cells with 4N DNA content (Fig. 5A) . Notably, these cells showed no evidence of an apoptotic response. These cells were then examined before and after doxorubicin treatment using the MTT assay. Viability of cells infected with either empty adenovirus or Ad-25C for 4 days did not differ significantly from that of control cells (Fig. 5B) . Similarly, reduction in cell growth following 3-day doxorubicin treatment was comparable in cells infected with empty adenovirus or Ad-25C and the controls (Fig. 5B) . These results suggest that elevated amounts of Cdc25C do not impose a negative effect on viability of MCF10A cells during this time course. Further, these data suggest that MCF10A cells arrest in G 1 -S rather than G 2 -M on expression of excess Cdc25C. The Annexin V-PE staining assay was then used as a more sensitive means of detecting apoptotic cells to see whether overexpression of Cdc25C affects death in MCF10A cells. Control and Ad-25C-infected cells were treated with 0.05 Ag/mL doxorubicin and harvested at the same time points as described for the MTT assays. Percentages of apoptotic Ad-25C-infected cells at 3 days post-treatment with doxorubicin were comparable with that found in control cells (Fig. 5C  and D) . This further confirms that overexpression of Cdc25C does not cause enhanced toxicity in nontransformed MCF10A cells. Treatment of either the controls or cells infected with empty adenovirus with 5-FU or hydroxyurea caused a G 1 -S accumulation that was not affected on infection with Ad-25C (Fig. 5A) . Thus, the ability of high levels of Cdc25C to sensitize cells to apoptosis correlates with the transformation phenotype of the cells being examined. This suggests that overexpression of Cdc25C may selectively enhance doxorubicin-induced cell death in tumor cells rather than in nontransformed cells.
Lack of Cdc25C Does Not Affect Cell Cycle Progression or the G 2 Arrest Caused by Doxorubicin
Mice lacking Cdc25C develop normally and their cell cycle checkpoints appear to be intact (21, 22) . To address the effects of loss of Cdc25C expression, Cdc25C was eliminated by the means of a small interfering RNA approach in U2OS cells. Manipulation of the related Cdc25A was included as a control. As shown in Fig. 6A , the majority of Cdc25C and Cdc25A were successfully down-regulated. As judged from flow cytometry analysis, lack of Cdc25A resulted in accumulation of cells with a 4N DNA content with a concomitant decrease of cells with 2N DNA content (Fig. 6B) . Lack of Cdc25C, however, did not affect cell cycle progression during the course of study (5 days; Fig. 6B ). The phosphorylation status of Cdk1 on Thr 14 and Tyr 15 by immunoblotting was then examined. Consistent with the flow cytometry analysis, absence of Cdc25C did not affect the levels of phosphorylation on these residues in comparison with control cells (Fig. 6A) . Lack of Cdc25A, on the other hand, led to an increase in the phosphorylated form of Cdk1 on these residues (Fig. 6A) . Next, the effect of absence of Cdc25C on the response of U2OS cells to doxorubicin was examined. The number of cells accumulated with a 4N DNA content was almost the same as in control cells (Fig. 6C) .
Discussion
Evidence provided in this study supports overexpression of Cdc25C as a bona fide abrogator of the G 2 checkpoint. It is noteworthy that there is little effect of high levels of Cdc25C on the G 1 -and S-phase checkpoints (4). Here, it is shown that excess amounts of Cdc25C abrogates the G 2 arrest caused by two common chemotherapeutic agents, doxorubicin and 5-FU, whereas it does not affect the G 1 -S-and S-phase arrests caused by 5-FU and hydroxyurea in several cell lines. Interestingly, these observations were made in cell lines derived from different tissues. This suggests that Cdc25C may have utility to abrogate the Cdc25C Enhances Chemotherapeutic Response G 2 arrest in cancer cells from various origins. Of great interest is the observation that the same amount of Cdc25C that is capable of overcoming the G 2 arrest does not affect the normal cell cycle progression of the examined cell lines including one that is nontumorigenic. To date, there is no reported evidence of overexpression of Cdc25C in human tumors in contrast to the other two related phosphatases, Cdc25A and Cdc25B (23) . Furthermore, as observed here, Cdc25C needs to be overexpressed at considerably high levels (when endogenous Cdc25C is not detectable) for it to overcome the G 2 arrest. This strongly suggests minimal toxicity caused by overexpression of Cdc25C even in a nontumorigenic line such as MCF10A. Importantly, Cdc25C did not sensitize this latter nontransformed cell line to doxorubicin-induced cell death. In this case, cells failed to arrest in G 2 -M at the examined time points, further confirming the role of Cdc25C in the G 2 checkpoint. This is a desirable result as proliferation of cells harboring DNA damage following chemotherapy is an unwanted outcome. Loss of a G 2 arrest has been reported to lead to a phenomenon called mitotic catastrophe, which results in formation of large micronucleated cells with decondensed chromatin (24) . Examination of MCF10A cells overexpressing Cdc25C and treated with doxorubicin revealed no morphologic changes consistent with mitotic catastrophe. This, however, does not exclude death as a result of apoptosis or mitotic catastrophe in other types of nontransformed cells when exposed to elevated levels of Cdc25C and doxorubicin.
In this study, lack of Cdc25C did not affect cell cycle progression of U2OS cells or their response to doxorubicin. Furthermore, mice lacking Cdc25C develop normally and the integrity of the DNA damage checkpoints of their embryonic fibroblasts remains intact (21, 22) . Based on these observations and a lack of alteration of Cdc25C in many human tumors, it is reasonable to postulate that Cdc25C is unlikely to be involved in any other cellular processes and, if so, it is likely to be a redundant player.
Two major obstacles encountered with many chemotherapeutic agents include their adverse side effects and the resistance developed against them. In addition, they often need to be used in combination for a positive therapeutic outcome. Often, however, this further increases undesirable side effects. Thus, it is expected that a combination of high levels of Cdc25C and such drugs would provide the opportunity for reducing the level of drug actually used and hence toxicity. These results support the idea that a combination of overexpressing Cdc25C with treatment with conventional genotoxic agents should be given serious considerations as a novel therapeutic strategy.
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